Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 420 participants.

Also called NCT07083154

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07083154
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07083154. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-27 (actual); primary completion 2029-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Condition
Dementia, Mild
Condition
Mild Cognitive Impairment
Intervention (Drug)
Mazdutide
Intervention (Drug)
Placebo
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (class: other)
Collaborator
Nanjing First Hospital, Nanjing Medical University (class: other)
Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (class: other)
Collaborator
Xiangya Hospital of Central South University (class: other)
Collaborator
Huadong Hospital (class: other)
Collaborator
Jiangsu Province Hospital of Traditional Chinese Medicine (class: other)
Collaborator
Changzhou No.2 People's Hospital (class: other)
Collaborator
The Second Affiliated Hospital of Dalian Medical University (class: other)

Record details

Record id
cardio:ct-nct07083154
Content hash
0c83b8f3da0041e562ec999effaa02aa726edade36c808f2ef7a9cb953dd270a